Search research articles
Contact Us
Filters
Showing results (21-30 of 34) with videos related to
Page
of 4
Sort By:
European Journal of Pain (London, England)
|
May 6, 2026
Sustained Attention Instability as a Cognitive Biomarker in Chronic Spine Pain: A 90-second Visual Attention Test
Kai-Uwe Lewandrowski, Kenneth Blum, Morgan Lorio, et al.
Journal of the Neurological Sciences
|
September 29, 2023
Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry
Kenneth Blum, J Wesson Ashford, Babak Kateb, et al.
Journal of Addiction Psychiatry
|
January 2, 2024
Are We Getting High Cause the Thrill is Gone?
Kenneth Blum, Thomas Mclaughlin, Mark S Gold, et al.
Current Neuropharmacology
|
September 25, 2025
PGx-Based in silico Analyses Identifies the Interactive Role of Genes, Glucose Metabolism and Dopaminergic Dysfunctional Pathways with Chronic Cocaine use and Misuse
Alireza Sharafshah, Panayotis K Thanos, Albert Pinhasov, et al.
INNOSC Theranostics & Pharmacological Sciences
|
May 20, 2024
Addressing cortex dysregulation in youth through brain health check coaching and prophylactic brain development
Kenneth Blum, Eric R Braverman, Mark S Gold, et al.
Journal of Personalized Medicine
|
March 26, 2025
Genetic and Regulatory Mechanisms of Comorbidity of Anxiety, Depression and ADHD: A GWAS Meta-Meta-Analysis Through the Lens of a System Biological and Pharmacogenomic Perspective in 18.5 M Subjects
Kai-Uwe Lewandrowski, Kenneth Blum, Alireza Sharafshah, et al.
Open Journal of Immunology
|
November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies
Kenneth Blum, Igor Elman, David Han, et al.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 34) with videos related to
Sort By:
Page
of 4
European Journal of Pain (London, England)
|
May 6, 2026
Sustained Attention Instability as a Cognitive Biomarker in Chronic Spine Pain: A 90-second Visual Attention Test
Kai-Uwe Lewandrowski, Kenneth Blum, Morgan Lorio, et al.
Journal of the Neurological Sciences
|
September 29, 2023
Dopaminergic dysfunction: Role for genetic & epigenetic testing in the new psychiatry
Kenneth Blum, J Wesson Ashford, Babak Kateb, et al.
Journal of Addiction Psychiatry
|
January 2, 2024
Are We Getting High Cause the Thrill is Gone?
Kenneth Blum, Thomas Mclaughlin, Mark S Gold, et al.
Current Neuropharmacology
|
September 25, 2025
PGx-Based in silico Analyses Identifies the Interactive Role of Genes, Glucose Metabolism and Dopaminergic Dysfunctional Pathways with Chronic Cocaine use and Misuse
Alireza Sharafshah, Panayotis K Thanos, Albert Pinhasov, et al.
INNOSC Theranostics & Pharmacological Sciences
|
May 20, 2024
Addressing cortex dysregulation in youth through brain health check coaching and prophylactic brain development
Kenneth Blum, Eric R Braverman, Mark S Gold, et al.
Journal of Personalized Medicine
|
March 26, 2025
Genetic and Regulatory Mechanisms of Comorbidity of Anxiety, Depression and ADHD: A GWAS Meta-Meta-Analysis Through the Lens of a System Biological and Pharmacogenomic Perspective in 18.5 M Subjects
Kai-Uwe Lewandrowski, Kenneth Blum, Alireza Sharafshah, et al.
Open Journal of Immunology
|
November 7, 2024
The First Pilot Epigenetic Type Improvement of Neuropsychiatric Symptoms in a Polymorphic Dopamine D2 (-DRD2/ANKK (Taq1A)), OPRM1 (A/G), DRD3 (C/T), and MAOA (4R) Compromised Preadolescence Male with Putative PANDAS/CANS: Positive Clinical Outcome with Precision-Guided DNA Testing and Pro-Dopamine Regulation (KB220) and Antibacterial Therapies
Kenneth Blum, Igor Elman, David Han, et al.
Current Pharmaceutical Biotechnology
|
April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis Era
Alireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Current Neuropharmacology
|
January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use Disorder
Alireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
Acta Scientific Neurology
|
September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) Screening
Kai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
Page
of 4